Image by Wyman Meinzer

Board of Directors 

Warren Huff   Founding Chief Executive Officer and President

Warren is the Chairman, Chief Executive Officer and President of Reata Pharmaceuticals.  He has served as the company's sole CEO and President since its founding in 2002.  Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises including Ergo Science Corporation, Light Biology, OpenPages, and InLight.  Warren started his career as an attorney with Johnson & Gibbs, P.C., a large institutional law firm, where he was a Senior Partner and Chairman of the Corporate Securities Practice.  Warren received a B.B.A.magna cum laudefrom the University of Texas at Austin and a J.D. from Southern Methodist University.

James Bass   Ojai Goliad, LLC

James is a Co-founder and Principal of Ojai Goliad, LLC. He was previously an executive director of an Asian regional investment bank based in Hong Kong. Prior to that he was an attorney over a 9-year period with Gibson, Dunn & Crutcher LLP in both California and Hong Kong and served as a managing partner of the firm's Hong Kong office in the mid 1990s. James graduated with a B.A. degree from Yale University and obtained his J.D. degree from Stanford University. 

R. Kent McGaughy, Jr.   CPMG, Inc.

Kent is a partner in CPMG, Inc. Prior to joining CPMG's predecessor, Cardinal Investment Company in 1997, he worked in mergers and acquisitions at Simmons & Company International. He currently serves on the boards of several private companies. Kent received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School.

Jack B. Nielsen   Novo Ventures

Jack is a Partner with Novo Ventures, a life science investment organization associated with Novo Nordisk. In this capacity, he is currently or has in the past been on board of directors of Panacos Pharmaceuticals, Cell Biosciences, NeoMend, Mediquest, CardioOptics, Inc. and Protein Forest. Prior to joining the venture organization, he held various management positions within Novo Nordisk.  Jack received his MSc from the Technical University of Denmark and his Masters in Management of Technology from the Center for Technology, Economics, and Management. 

Edward W. “Rusty” Rose   Cardinal Investment Company, Inc

Rusty founded Cardinal Investment Company, Inc. in 1973, and is the firm's President.  He serves on the boards of several private companies, and is on the board of Drew Industries, Inc. (NYSE:  DW).  He is the former Co-managing Partner of the Texas Rangers. Rusty received his B.S. from The University of Texas and his M.B.A. from Harvard Business School.

Dennis Stone, M.D.   Remeditex Ventures

Dennis is Chief Scientific Officer and a Director of Remeditex Ventures. He joined Remeditex from UT Southwestern Medical Center (UTSW) where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development since 1998. During his tenure, Dennis and his team created over $100M in and launched six start-up biotechnology companies that collectively raised over $500 million in financing. He has participated on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., MacroGenics, Inc., and Reata Pharmaceuticals, Inc. In addition, he served as the Chairman of the U.T. Regents' Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Fund's Life Science Commercialization Center. Dennis has received his undergraduate training in the Plan II at The University of Texas at Austin and his medical degree from UTSW.

Nancy Wysenski  

Nancy served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from 2009 to 2012. In this role, she built out the commercial organization from 40 to almost 400 employees and successfully launched Vertex's first two products. INCIVEK sales reached $1 billion in less than a year, faster than any product in pharma history. Six months later, KALYDECO was launched as an orphan drug for the treatment of Cystic Fibrosis. Prior to joining Vertex, Nancy held the position of Chief Operating Officer at Endo Pharmaceuticals, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, she was a co-founder of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, where she held various leadership positions, including the role of President and CEO from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Nancy held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc.